A 52-year-old man with chronic kidney disease (eGFR 28 mL/min/1.73m²) presents with fatigue and dyspnea. His hemoglobin is 7.8 g/dL, MCV 82 fL, reticulocyte count 1.2% (normal 0.5–2.5%). Iron studies are normal. What is the most appropriate next step in management?

Explanation

## Clinical Diagnosis The patient has normocytic anemia (MCV 82 fL) with low reticulocyte count (1.2%) in the setting of chronic kidney disease (CKD). Normal iron studies exclude iron deficiency. This is anemia of chronic kidney disease (CKD-related anemia), primarily due to EPO deficiency. ## Pathophysiology of CKD-Related Anemia **Key Point:** In CKD, the kidneys produce <10% of normal EPO, leading to inadequate RBC production despite intact bone marrow function. The reticulocyte count is inappropriately low for the degree of anemia, confirming hypoproliferative anemia. ## Management Algorithm for CKD Anemia ```mermaid flowchart TD A[CKD patient with anemia]:::outcome --> B[Check iron studies]:::action B --> C{Iron replete?}:::decision C -->|No| D[Correct iron deficiency first]:::action C -->|Yes| E[Check reticulocyte count]:::decision E -->|Low| F[Hypoproliferative anemia]:::outcome F --> G{Hb target achieved?}:::decision G -->|No| H[Start ESA therapy]:::action G -->|Yes| I[Continue maintenance ESA]:::action H --> J[Monitor Hb, iron, BP]:::action ``` **High-Yield:** ESA (erythropoietin or darbepoetin alfa) is the first-line pharmacologic therapy for CKD anemia once iron stores are adequate. Do NOT measure serum EPO levels — they are elevated in CKD but remain insufficient to drive erythropoiesis. Clinical response (Hb rise) is the measure of ESA efficacy. ## Why NOT Measure EPO Level | Test | CKD Anemia | Rationale | | --- | --- | --- | | Serum EPO | Elevated (100–500 mIU/mL) | Kidneys cannot produce enough; absolute level is irrelevant | | Reticulocyte count | Low/inappropriately normal | Confirms hypoproliferative mechanism | | Iron studies | Normal (in this case) | ESA requires iron availability | | Bone marrow | Normal | Rules out other causes (aplasia, infiltration) | **Clinical Pearl:** Measuring serum EPO in CKD is a common misconception. EPO levels are already elevated in CKD; the problem is insufficient production relative to anemia severity. Starting ESA directly based on clinical criteria (Hb <10 g/dL in CKD) is the standard approach. **Tip:** Before starting ESA, ensure: 1. Iron stores adequate (ferritin >100 ng/mL, TSAT >20%) 2. No active infection or inflammation (CRP, WBC) 3. Reticulocyte count confirms hypoproliferation 4. Blood pressure controlled (ESA can raise BP) **Warning:** ESA target is Hb 10–12 g/dL in CKD; avoid Hb >13 g/dL due to increased thrombotic risk. Monitor for hypertension and thrombosis. [cite:Harrison 21e Ch 105; KDIGO 2021 Anemia in CKD]